Different regions of the brain and spinal cord house different, specialized cells. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing central nervous system (CNS) in virtually unlimited numbers from a single donated tissue. More

Neuralstem’s technology uniquely enables the creation of stable neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of new neurons. From these cell lines, the company can create practically unlimited amounts of hippocampal neural stem cells. More

    • Neuralstem Presented NSI-189 Preclinical Data in Type 1 and Type 2 Diabetes at the Annual Meeting of the Diabetic Neuropathy Study Group9.12.16

      GERMANTOWN, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell proprietary technology, announced that Karl Johe, Ph.D., Chief Scientific Officer, presented the poster, “Therapeutic Efficacy of NSI-189 in Diabetic Mice,” at the Annual Meeting of the Diabetic Neuropathy Study Group of the EASD (European Association for the Study of Diabetes), held in Bucharest, Romania, on September 11th. The data demonstrate the potential for NSI-189 to reverse neuropathies resulting from diabetes in two well-recognized animal models. More


    • Neuralstem Receives $20,000,000 Strategic Investment from Tianjin Pharmaceutical Group9.12.16

      GERMANTOWN, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that on September 7, 2016, it entered into definitive agreements with Tianjin Pharmaceutical Holding Group for the private placement of common stock and convertible preferred stock for gross proceeds of $20,000,000. More


    • Neuralstem Announces NSI-189 Shows Enhancement of Long-Term Potentiation In Vitro 6.21.16

      GERMANTOWN, Md., June 21, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that new in vitro data on NSI-189 provide insight into the neurogenic drug’s mode of action. More


    • Neuralstem Announces New Chairman and Further Reorganization Plans 6.13.16

      GERMANTOWN, Md., June 13, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced, in furtherance of its reorganization plans and focus on clinical development, that Richard Daly, the company’s president and chief executive officer, has been appointed chairman of the board of directors. More